Chiesi Farmaceutici S.p.A.
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
Inclusion Criteria: * Male or female aged \> 18 years of age at the time of consent. * Genetically confirmed diagnosis of Fabry disease. * Either taking or planning to take pegunigalsidase alfa as treatment for Fabry disease. * No contraindications for cardiac magnetic resonance imaging (cMRI) * Informed consent form (ICF) signed and dated indicating the individual has been informed of and agreed to all pertinent aspects of the study and is willing to comply with all study requirements, including completion of electronic patient reported outcomes (ePROs). * Cardiac Cohort: * Evidence of Fabry…
Administered via intravenous (IV) infusion under conditions of routine clinical care